Palisade Bio Statistics

Total Valuation

Palisade Bio has a market cap or net worth of $2.33 million. The enterprise value is -$5.37 million.

Market Cap	2.33M
Enterprise Value	-5.37M

Important Dates

The last earnings date was Tuesday, November 12, 2024, before market open.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Palisade Bio has 1.33 million shares outstanding. The number of shares has increased by 210.81% in one year.

Current Share Class	1.33M
Shares Outstanding	1.33M
Shares Change (YoY)	+210.81%
Shares Change (QoQ)	+22.14%
Owned by Insiders (%)	1.67%
Owned by Institutions (%)	1.76%
Float	1.18M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.32
P/TBV Ratio	0.35
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.31, with a Debt / Equity ratio of 0.05.

Current Ratio	3.31
Quick Ratio	3.04
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,108.15

Financial Efficiency

Return on equity (ROE) is -135.96% and return on invested capital (ROIC) is -83.58%.

Return on Equity (ROE)	-135.96%
Return on Assets (ROA)	-68.20%
Return on Capital (ROIC)	-83.58%
Revenue Per Employee	n/a
Profits Per Employee	-$1.56M
Employee Count	9
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -80.47% in the last 52 weeks. The beta is 1.31, so Palisade Bio's price volatility has been higher than the market average.

Beta (5Y)	1.31
52-Week Price Change	-80.47%
50-Day Moving Average	2.61
200-Day Moving Average	4.17
Relative Strength Index (RSI)	41.27
Average Volume (20 Days)	3,696,383

Short Selling Information

The latest short interest is 107,548, so 8.09% of the outstanding shares have been sold short.

Short Interest	107,548
Short Previous Month	114,682
Short % of Shares Out	8.09%
Short % of Float	9.10%
Short Ratio (days to cover)	0.29

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-14.41M
Pretax Income	-13.50M
Net Income	-14.07M
EBITDA	-14.40M
EBIT	-14.41M
Earnings Per Share (EPS)	-$13.65

Full Income Statement

Balance Sheet

The company has $8.05 million in cash and $357,000 in debt, giving a net cash position of $7.70 million or $5.79 per share.

Cash & Cash Equivalents	8.05M
Total Debt	357,000
Net Cash	7.70M
Net Cash Per Share	$5.79
Equity (Book Value)	6.61M
Book Value Per Share	5.51
Working Capital	6.19M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-12.56M
Capital Expenditures	n/a
Free Cash Flow	-12.56M
FCF Per Share	-$9.45

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Palisade Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-210.81%
Shareholder Yield	-210.81%
Earnings Yield	-604.52%
FCF Yield	-539.75%

Analyst Forecast

The average price target for Palisade Bio is $23.00, which is 1,214.29% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$23.00
Price Target Difference	1,214.29%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-27.83%

Stock Forecasts

Stock Splits

The last stock split was on April 8, 2024. It was a reverse split with a ratio of 0.0666667:1.

Last Split Date	Apr 8, 2024
Split Type	Reverse
Split Ratio	0.0666667:1

Scores

Palisade Bio has an Altman Z-Score of -23.12 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-23.12
Piotroski F-Score	1